• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

atricure

AtriCure treats first patient in Isolator Synergy clamp trial

June 7, 2022 By Sean Whooley

AtriCure (Nasdaq:ATRC) announced today that it treated the first patient in its HEAL-IST clinical trial in Belgium. Dr. Mark LaMeir and Dr. Carlo de Asmundis treated the first patient in the HEAL-IST trial evaluating the AtriCure Isolator Synergy clamp for treating drug-refractory patients diagnosed with inappropriate sinus tachycardia (IST) at University Hospital Brussels. “Symptomatic IST […]

Filed Under: Cardiovascular, Clinical Trials, Vascular Tagged With: atricure, AtriCure Inc.

AtriCure beats The Street in Q1 results

May 4, 2022 By Danielle Kirsh

AtriCure (Nasdaq:ATRC) this week posted first-quarter results that beat the overall consensus on Wall Street. The Mason, Ohio-based cardiac ablation device company reported losses of $15.2 million, or -34¢ per share, on sales of $74.6 million for three months ended March 31, for a bottom-line gain of 10.3% on sales growth of 25.8% compared with […]

Filed Under: Business/Financial News, Cardiovascular, MassDevice Earnings Roundup, Wall Street Beat Tagged With: atricure

AtriCure launches clamp for cardiac tissue ablation

April 12, 2022 By Sean Whooley

AtriCure (Nasdaq:ATRC) announced today that it launched the EnCompass Clamp as part of its Isolator Synergy ablation system. Mason, Ohio-based AtriCure received FDA 510(k) clearance for the EnCompass Clamp for the ablation of cardiac tissue during cardiac surgery to make concomitant surgical ablations more efficient. According to a news release, the platform includes parallel closure, […]

Filed Under: 510(k), Business/Financial News, Cardiac Implants, Cardiovascular, Food & Drug Administration (FDA), Radiosurgery/Radiation therapy, Regulatory/Compliance, Structural Heart Tagged With: atricure, AtriCure Inc.

These 10 medtech companies’ stocks performed best in 2021

March 7, 2022 By Sean Whooley

Following a year like no other in 2020, 2021 was when many looked to rebound — including the medtech industry. A number of medtech companies followed up a challenging, pandemic-enveloped year with impressive performances. Plenty of them had already proven in 2020 that they were capable of a quick bounce-back. Here are 10 medtech companies […]

Filed Under: Business/Financial News, Cardiovascular, Diabetes, Featured, News Well, Orthopedics, Wall Street Beat Tagged With: Abbott, Abiomed, atricure, Bio-Rad, Dexcom, Edwards Lifesciences, ICU Medical, Inspire Medical Systems Inc., ResMed, Stryker

AtriCure publishes first environmental, social, governance report

February 16, 2022 By Danielle Kirsh

AtriCure (NASDAQ:ATRC) this month released its first environmental, social and governance (ESG) report that highlights the company’s corporate responsibility and sustainability initiatives. Companies produce corporate responsibility for corporate stakeholders who are interested in ESG-related information. AtriCure’s ESG report includes data metrics such as the gender diversity of its management and workforce and the racial diversity […]

Filed Under: Business/Financial News, Cardiovascular, News Well Tagged With: atricure

AtriCure posts Street-beating Q3 results, maintains full-year outlook

November 4, 2021 By Jim Hammerand

AtriCure (NSDQ:ATRC) posted third-quarter results today that beat the consensus forecast on Wall Street and maintained its outlook for the full year. The Mason, Ohio-based atrial fibrillation (AFib) technology developer reported profits of $97.1 million, or $2.11 per diluted share, on sales of $70.5 million for the three months ended Sept. 30. Sales grew 28.7% […]

Filed Under: Blog, Business/Financial News, Cardiovascular, Catheters, Clinical Trials, Featured, MassDevice Earnings Roundup, News Well Tagged With: AFib, atrial fibrillation, atricure, EPi-Sense

DTW Podcast: How AtriCure built a big business in Afib; A deep look into Abbott’s new Coronary imaging platform

May 24, 2021 By Tom Salemi

In this week’s episode of the DeviceTalks Weekly Podcast, Dr. Nick West, CMO & divisional VP of global medical affairs at Abbott’s vascular business, discusses the European launch of the company’s new coronary imaging platform. Dr. West explains how the AI-powered platform works and the benefits it offers for decision-making during coronary stenting procedures. He […]

Filed Under: Cardiovascular, Catheters, Clinical Trials, Device Talks Podcasts, Featured, Imaging, Special Content Tagged With: Abbott, atricure, DeviceTalks Weekly, Google, Medtronic, Teleflex, Teleflex Medical

5 of the latest cardiac tech insights out of ACC.21

May 17, 2021 By Nancy Crotti

The American College of Cardiology’s 70th Annual Scientific Session has produced some positive news about some controversial cardiac tech. Drug-coated stents, which a 2018 study linked to late-stage death, were shown to be non-inferior to non-drug-coated stents in patients with peripheral arterial disease. And a new study of renal denervation that used a different methodology […]

Filed Under: Cardiac Implants, Cardiovascular, Catheters, Clinical Trials, Drug-Device Combinations, Drug-Eluting Stents, Featured, Implants, Replacement Heart Valves, Stents, Vascular Tagged With: American College of Cardiology, atricure, Beth Israel Deaconess Medical Center, Boston Scientific, Edwards Lifesciences, Medtronic, ReCor Medical

AtriCure AFib treatment device wins FDA approval

April 29, 2021 By Sean Whooley

AtriCure (NSDQ:ATRC) announced today that the FDA approved its EPi-Sense system for treating long-standing persistent atrial fibrillation (Afib). Mason, Ohio-based AtriCure’s EPi-Sense system demonstrated superiority in the Hybrid AF therapy arm compared to endocardial catheter ablation alone in the Converge clinical trial, according to a news release. AtriCure’s Hybrid AF therapy is a minimally invasive […]

Filed Under: Cardiovascular, Clinical Trials, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Structural Heart Tagged With: atricure, AtriCure Inc., FDA

AtriCure beats the Street in Q1 results

April 28, 2021 By Danielle Kirsh

AtriCure (NASDAQ:ATRC) posted first-quarter results today that beat the consensus forecast on Wall Street. The Mason, Ohio-based company reported losses of -$16.9 million, or -38¢ per share, on sales of $59.3 million for the three months ended March 31, for a sales growth of 11.37% compared with Q1 2020. Adjusted to exclude one-time items, earnings per […]

Filed Under: Cardiovascular, MassDevice Earnings Roundup, Wall Street Beat Tagged With: atricure

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS